Befetupitant (Ro67-5930) is a drug developed by
Hoffmann-La Roche which acts as a potent and selective
antagonist for the
NK1receptor.[1] It was originally developed as a potential
antiemetic drug, though development was ultimately discontinued after a related drug
netupitant was deemed to be more suitable for clinical development. Befetupitant has however continued to be researched for other possible applications such as treatment of
corneal neovascularization.[2]
References
^Hoffmann T, Bös M, Stadler H, Schnider P, Hunkeler W, Godel T, et al. (March 2006). "Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists". Bioorganic & Medicinal Chemistry Letters. 16 (5): 1362–5.
doi:
10.1016/j.bmcl.2005.11.047.
PMID16332435.
^Bignami F, Giacomini C, Lorusso A, Aramini A, Rama P, Ferrari G (September 2014). "NK1 receptor antagonists as a new treatment for corneal neovascularization". Investigative Ophthalmology & Visual Science. 55 (10): 6783–94.
doi:
10.1167/iovs.14-14553.
PMID25228541.